110 results about "Membrane binding" patented technology

The present invention relates to a biosensor which comprises an electrode system including at least one pair of electrodes, at least one insulating base plate for supporting the electrode system, a first reaction layer provided at least on a working electrode of the electrode system, including an organic compound having a functional group capable of bonding or being adsorbed to an electrode and a hydrophobic hydrocarbon group, a second reaction layer provided on the first reaction layer, including an amphiphilic lipid capable of bonding or being adsorbed to a hydrophobic portion of the first reaction layer, and a reagent system carried in a two-component membrane composed of the first and second reaction layers, including at least membrane-binding type pyrroquinoline quinone-dependent glucose dehydrogenase and an electron mediator.

An assay method and kit is disclosed for detecting the presence of at least one predesignated, target antibody to a mycobacterium in a sample selected from one or more patient bodily fluids. The method comprises the following steps: (a) contacting the sample of one or more patient bodily fluids with at least one mycobacterium antigen on a lateral-flow assay membrane to bind to the target antibody in the sample; (b) previously, simultaneously or subsequently to step (a), binding the at least one mycobacterium antigen with a conjugated label producing a detectable signal; and (c) detecting the signal whereby the presence of the target antibody is determined in the sample by the intensity or presence of the signal. The method can further comprise the step of evaluating immunization status of the patient from whom the sample came by comparing the signal or lack thereof with immunizations previously received by the patient and in comparison to a known standard control. In a preferred embodiment, the mycobacterium antigen specifically binds to Mycobacterium tuberculosis specific antibodies. Preferably, the immunoassay of the present invention comprises a lateral-flow assay comprising a membrane, a conjugated label pad, and at least one mycobacterium antigen bound to the membrane. In a preferred embodiment, the at least one mycobacterium antigen is selected from the group consisting of 38 kDa and 16 kDa antigens.

The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.

This invention provides to a novel gene encoding a protein aving the activity of beta-galactoside-alpha2,6-sialyltransferase.The gene of the invention encodes a protein which having the amino acid sequence of SEQ ID NO:1, or a protein having the amino acid sequence of SEQ ID NO:1 which have been modified by deletion, substitution or addition of at least one amino acid residue in said sequence, while maintaining substantially the same beta-galactoside-alpha2,6-sialyltransferase activity.The present invention uses said gene to further provide a vector for expressing a protein having the beta-galactoside-alpha2,6-sialyltransferase activity, host cells and a recombinant protein. The protein encoded by the gene of the invention does not have any substantial homology with known sialyltransferases, and in addition, the membrane binding region is located in the C-terminal unlike known sialyltransferases.

The present invention relates to molecules, preferably soluble (i.e., not membrane bound) polypeptides, most preferably soluble fusion polypeptides comprising the extracellular soluble regions of an Fc³R, derivatives and analogs thereof, and nucleic acids encoding the same. Molecules of the invention are particularly useful for the treatment, management, or prevention of, or amelioration of one or more symptoms of an autoimmune disease, especially for ameliorating serum platelet deficiency associated with immune thrombocytopenic purpura. The invention provides methods and compositions for enhancing the therapeutic efficacy of standard, current or experimental therapies for an autoimmune disease by administering a molecule of the invention.

Detection and characterization of molecular interactions on membrane surfaces is important to biological and pharmacological research. In one embodiment, silver nanocubes interfaced with glass-supported model membranes form a label-free sensor that measures protein binding to the membrane. The present device and technique utilizes plasmon resonance scattering of nanoparticles, which are chemically coupled to the membrane. In contrast to other plasmonic sensing techniques, this method features simple, solution-based device fabrication and readout. Static and dynamic protein / membrane binding are monitored and quantified.

A cross-protective influenza virus vaccine has been designed based on the incorporation of the genetically engineered, highly conserved M2 influenza viral protein optionally in combination with an adjuvant such as a bacterial flagellin protein incorporated into the membrane of a virosome or virus-like particles. Immunogenicity and the breadth of cross protection efficacy are significantly enhanced using multiple copies of the influenza M2 protein as a membrane bound tetramer and / or in combination with a membrane bound adjuvant. A method for vaccinating a subject for influenza A has also been developed that results in broad and improved cross-protection against multiple subtypes of influenza A virus.

An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.

A protein obtainable from a non pathogenic microorganism, said protein having mucosa binding promoting activity and a molecular weight of 20-40 kD is disclosed. Application of such a protein or a peptide derived therefrom in a method of screening non pathogenic microorganisms for a microorganism capable of specifically binding mucosa, said method comprising detection in a manner known per se of the presence of a particular protein on or in a microorganism or in a culture of microorganisms, said particular protein being the already defined protein. Kits suitable for such a screening method are also disclosed. Use of a component selected from the group of components comprising a protein or peptide as defined an expression vector comprising nucleic acid encoding such protein or peptide a recombinant microorganism or a part of said microorganism expressing such protein or peptide, said part expressing mucosa binding promoting activity a non pathogenic microorganism capable of expressing such protein or peptide or a part of said microorganism, said part expressing mucosa binding promoting activity as pharmaceutically active component in a pharmaceutical composition for prophylaxis and / or treatment of disease or illness associated with a mucosa colonising pathogenic microorganism. Use of such components as food additive and compositions comprising such components are described.

A protein obtainable from a non pathgenic microorgansim, said protein having mucosa binding promoting activity and a molecular weight of 20-40 kD is disclosed. Application of such a protein or a peptide derived therefrom in a method of screening non pathogenic microorganisms for a microorganism capable of specifically binding mucosa, said method comprising detection in a manner known per se of the presence of a particular protein on or in a microorganism or in a culture of microorganisms, said particular protein being the already defined protein. Kits suitable for such a screening method are also disclosed. Use of a component selected from the group of components comprising a protein or peptide as defined; an expression vector comprising nucleic acid encoding such protein or peptide; a recombinant microorganism or a part of said microorganism expressing such protein or peptide, said part expressing mucosa binding promoting activity; a non pathogenic microorganism capable of expressing such protein or peptide or a part of said microorganism, said part expressing mucosa binding promoting activity as pharmaceutically active component in a pharmaceutical composition for prophylaxis and / or treatment of disease or illness associated with a mucosa colonizing pathogenic microorganism. Use of such components as food additive and compositions comprising such components are described.

The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.

The invention discloses a human feces DNA extraction method. The prior art is complicated and time-consuming; and the trace DNAs extracted by the previous sampling method is too little to perform molecular diagnosis. The extraction method uses selective sample collection PSC equipment for feces samples and adopts a low temperature preservation method. The extraction method comprises the following steps: picking a sample by using a sterilized gun head or sterilized blade and directly placing the picked sample on ice; and adding a feces lysis solution, fully cracking and evenly mixing, adding bovine serum albumin, centrifuging to remove the supernatant, adding protease K to perform a digestion reaction at 58 DEG C, then adding a protein precipitation solution to precipitate the protein, centrifuging to obtain the supernatant, adding a silica gel membrane binding solution to fully bind DNAs, centrifuging to obtain precipitates, adding a silica gel membrane washing solution to wash twice, centrifuging, and adding a TE (Tris + EDTA) buffer solution to finally obtain a preservation solution with DNAs. The human feces DNA extraction method has the advantages of high repeatability and stability, simpleness and short time.

The invention discloses a multi-target chimeric antigen receptor. The multi-target chimeric antigen receptor provided by the invention consists of a main peptide chain and an assistant peptide chain.The main peptide chain includes an antigen binding domain A, an assistant peptide chain connection domain B, a transmembrane domain C and an intracellular signal conduction domain D. The assistant peptide chain includes a main peptide chain connection domain F. The antigen binding domain A is a polypeptide with antigen-bonding function. The assistant peptide chain connection domain B and the mainpeptide chain connection domain F are mutually combined. The transmembrane domain C is the transmembrane domain of arbitrary membrane binding protein or the transmembrane domain of transmembrane protein. The intracellular signal conduction domain D includes a primary signal conduction region. The multi-target chimeric antigen receptor provided by the invention can mediate specific cell killing bycombining two antigen binding domains with different antigens. Also a cytokine and cytokine receptor compound are introduced into the multi-target chimeric antigen receptor provided by the invention and can play the role of cytokines.

The present invention relates to membrane binding diastereomeric peptides comprising amino acid sequences corresponding to a fragment of a transmembrane proteins, wherein at least two amino acid residues of the diastereomeric peptides being in a D-isomer configuration. The diastereomeric peptides are useful in inhibiting fusion membrane protein events, including specifically viral replication and transmission.

The present invention relates to modified forms of IL-12. These modified forms of IL-12 may be engineered to have a shortened in vivo half-life compared and / or enhanced localization of biological effects compared to that of corresponding non-modified form of IL-12. Short half-life and membrane bound forms of IL-12 may provide greater therapeutic control for in vivo therapeutic delivery, in particular when used in combination with ligand inducible delivery of IL-12. Modified forms of IL-12 engineered to have shortened in vivo half-life and / or enhanced localization of biological effects include heterodimeric p35 / p40, single chain and membrane bound forms of IL-12 wherein a naturally occurring IL-12 amino acid sequence is genetically modified to enhance susceptibility of the IL-12 molecule to in vivo proteolytic degradation.

Methods and compositions for binding to the membrane-bound form of IL1 RAP. In some embodiments, the invention provides an isolated antibody that binds the membrane bound fom1 of human IL1 RAP. In some cases, the isolated antibody that binds the membrane-bound form of human IL1 RAP does not bind, or does not substantially bind, the soluble form of human IL1 RAP. For example, in some cases, the isolated antibody that binds the membrane-bound form of human IL1RAP does not bind, or does not substantially bind the soluble form of human IL1RAP that is found in normal human serum. In some cases, the soluble form of human IL1 RAP comprises the sequence GNRCGQ.

The invention provides vitamin k-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.

Recombinant microbial cells are disclosed herein that produce an oil comprising at least 28 percent eicosapentaenoic acid (EPA) measured as a weight percent of dry cell weight. These cells may comprise a polynucleotide sequence encoding an active acyl-CoA:lysophosphatidylcholine acyltransferase (LPCAT) comprising at least one amino acid mutation in a membrane-bound O-acyltransferase motif. In addition, the cells may comprise a down-regulation of an endogenous polynucleotide sequence encoding Sou2 sorbitol utilization protein, and / or one or more polynucleotides encoding phospholipid:diacylglycerol acyltransferase (PDAT), delta-12 desaturase, a dihomo-gamma-linolenic acid (DGLA) synthase multizyme, delta-8 desaturase, malonyl-CoA synthetase (MCS), or acyl-CoA:lysophosphatidic acid acyltransferase (LPAAT). Also disclosed are methods of using the recombinant microbial cells to produce oil containing omega-3 polyunsaturated fatty acids such as EPA.

A delivery system for introducing a cargo molecule into cytosol of a living cell can include: a first membrane binding element linked to an endosomal compartment disrupting element through a first linker having one or more anionic moieties; and a second membrane binding element linked to an exogenous cargo molecule through a second linker having one or more anionic moieties, the second linker having a region that is selectively cleavable, wherein the first and second membrane binding elements both induce endocytosis into an early / recycling endosome and the endosomal compartment disrupting element destabilizes the early / recycling endosome such that the exogenous cargo molecule is released from the second membrane binding element and into the cytosol of the living cell.

The present invention provides nucleic acid molecules encoding annexin 1 (ANX1) and annexin 4 (ANX4) that belong to a multigene family of calcium-dependent membrane binding proteins. ANX1 and ANX4 are inducible by abscisic acid (ABA), salt and other various stress treatments. The anx1 and anx4 mutant plants are characterized by their hypersensitivity to salt and ABA during seed germination and early seedling growth. The invention can be utilized to generate transgenic plants that are tolerant to environmental stress.

The invention discloses a chimeric antigen receptor (CAR) gene for expressing a soluble PD-1, and application of the CAR gene. The CAR gene comprises an antigen binding domain gene, a transmembrane domain gene, an intracellular domain gene and a soluble PD-1 gene which are sequentially connected, the soluble PD-1 is an extracellular domain area of the PD-1, and preferably, the soluble PD-1 includes an amino acid sequence shown in SEQ ID No.1. CAR-T cells can secrete sPD-1 in a tumor microenvironment, through combination of sPD-1 and PD-L1 on the surfaces of tumor cells, combination with transmembrane PD-1 on the surfaces of the CAR-T cells is inhibited competitively, thus inhibition of the CAR-T cells is avoided, the killing and treating effects of the CAR-T cells on the tumor cells are improved, and the purpose of treating tumors, especially solid tumors, is achieved. A new way is provided for improving the effect of the CAR-T cells on killing the tumor cells.

The present invention relates to the detection of HLA-G. Antibodies to both soluble and membrane bound HLA-G are disclosed. Exemplary antibodies include 2C / C8, 3C / G4, and 4H84. 2C / C8 and 4H84 antibodies bind to the same region of HLA-G, which is a different region than that bound by 3C / G4. Methods of detection and diagnosis are disclosed as well as kits, including a miniaturized assay suitable for a clinical setting. Further, a method of selecting an embryos for in vitro fertilization is disclosed. A sandwich ELISA test is provided using two antibodies that bind to HLA-G at different regions. The HLA-G test according to the invention is over 1000 times more selective in binding to HLA-G than to antigens HLA-A2, HLA-B4, HLA-C, or mixed WBC preparations.

The present invention relates to improved anti-CD73 antibodies which, in comparison to prior art anti-CD73 antibodies bind to a membrane-bound form of CD73 protein having cancer-promoting role and inhibit its enzymatic activity, while essentially not inhibiting a soluble form of CD73 protein involved in cardioprotection. The present invention further relates to methods of generation of such specific anti-CD73 antibodies and uses thereof including uses as medicaments and in methods for treatment, amelioration, prophylaxis and diagnostics of cancer.

A delivery system for introducing a cargo molecule into cytosol of a living cell can include: a first membrane binding element linked to an endosomal compartment disrupting element through a first linker having one or more anionic moieties; and a second membrane binding element linked to an exogenous cargo molecule through a second linker having one or more anionic moieties, the second linker having a region that is selectively cleavable, wherein the first and second membrane binding elements both induce endocytosis into an early / recycling endosome and the endosomal compartment disrupting element destabilizes the early / recycling endosome such that the exogenous cargo molecule is released from the second membrane binding element and into the cytosol of the living cell.

The present disclosure provides methods and compositions for genetically modifying lymphocytes and related methods that include genetically modifying T cells and / or NK cells. The methods use replication incompetent recombinant retroviral particles that comprise a pseudotyping element on their surface and optionally a membrane-bound T cell activation element, such as an anti-CD3, and encode one ormore engineered signaling polypeptides that can include a lymphoproliferative element, and / or a chimeric antigen receptor (CAR). The methods can include contacting PBMCs with replication incompetent recombinant retroviral particles for various exemplary time periods, such as less than 24 hours or in some illustrative embodiments less than 15 minutes. Illustrative chimeric lymphoproliferative elements that are capable of promoting survival and / or proliferation of T cells or NK cells in culture without adding IL-2, are provided. Furthermore, additional regulatory elements are provided, such as inhibitory RNA molecules.

The reagent card for quantitatively detecting the helicobacter pylori antibody by fluorescence chromatography comprises a card shell and a test strip arranged in the card shell, wherein the test stripcomprises a bottom plate, and a nitrocellulose membrane, a conjugate pad and a sample pad which are adhered to the bottom plate; the sample pad, the conjugate pad and the nitrocellulose membrane aresequentially overlapped end to end for a preset length; the nitrocellulose membrane is coated with a helicobacter pylori natural antigen through lineation; and lanthanide-labeled latex microspheres coated with helicobacter pylori recombinant protein antigens are sprayed on the conjugate pad. The reagent card provided by the invention is a helicobacter pylori antibody lanthanide time-resolved fluorescence chromatography quantitative detection reagent card prepared by adopting a helicobacter pylori recombinant protein antigen and natural antigen combined double-antigen sandwich method, and can realize rapid quantitative detection of a helicobacter pylori antibody (IgG antibody). Correspondingly, the invention further provides a detection method for quantitatively detecting the helicobacter pylori antibody through fluorescence chromatography.

The present invention relates to improved anti-CD73 antibodies which, in comparison to prior art anti-CD73 antibodies bind to a membrane-bound form of CD73 protein having cancer-promoting role and inhibit its enzymatic activity, while essentially not inhibiting a soluble form of CD73 protein involved in cardioprotection. The present invention further relates to methods of generation of such specific anti-CD73 antibodies and uses thereof including uses as medicaments and in methods for treatment, amelioration, prophylaxis and diagnostics of cancer.

The invention relates to the technical field of brewing of Baijiu, and in particular to extraction of microbial genome DNA in fermented grains. The method comprises the following steps: (1) wall breaking of microbial cells in the fermented grains: weighing a fermented grain sample and quartz sand, adding lysate, and conducting shaking centrifugation so as to obtain a coarse nucleic acid extracting solution; and (2) nucleic acid purification: adding a mixture of phenol: chloroform: isoamylol (P.C.I), conducting centrifugation to remove protein, adding a silica gel membrane binding solution, conducting filtering by virtue of a nucleic acid purification column, eluting the nucleic acid purification column by virtue of 70% ethanol, adding de-ionized water or a TE solution and preserving the DNA. The method is simple and convenient to operate, low in cost consumption, low in labor intensity and time-saving, and the extracted microbial genome in the fermented grains is high in quality and is applicable to such molecular biology analysis as next generation sequencing, fluorescent quantitative PCR and the like.